Weekly Digest – April 2024 Weekly Digest – April 2024 26 Apr 2024: Breast cancer drug Enhertu’s breakthrough results unveiled at GBCC 2024 GBCC symposium reveals Enhertu’s breakthrough in HER2+ breast cancer: data presented highlights significant improvements in PFS and […]
Weekly Digest – April 2024 Weekly Digest – April 2024 17 Apr 2024: Bristol Myers Squibb finalizes a Global Strategic License and Collaboration Agreement with SystImmune for BL-B01D1, bolstering its position in the ADC arena Bristol Myers Squibb has completed […]
Weekly Digest – April 2024 Weekly Digest – April 2024 23 Apr 2024: Tharimmune Enters Option Agreement for Crucial Technologies in HER2/HER3 Antibody Drug Conjugates Tharimmune, Inc. secures an option agreement for an exclusive license with Washington University for the […]
Weekly Digest – April 2024 Weekly Digest – April 2024 22 Apr 2024: Salubris Biotherapeutics Secures $35 Million Investment and Unveils Pipeline Advancements Salubris Biotherapeutics, Inc. secured $35 million in new funding for ongoing research and development Clinical trial application […]
Weekly Digest – April 2024 Weekly Digest – April 2024 16 Apr 2024: ProPhase Labs unveils Project ZenQ-AI ProPhase Labs introduces Project ZenQ-AI for cancer treatment research, utilizing its advanced AI platform The platform, along with data from the BE-Smart […]
Weekly Digest – April 2024 Weekly Digest – April 2024 17 Apr 2024: BiVictriX Therapeutics AML treatment granted Orphan Drug status by FDA BiVictriX Therapeutics drug, BVX001, receives an Orphan Drug Designation (ODD) from the FDA to address a significant […]
Weekly Digest – April 2024 Weekly Digest – April 2024 16 Apr 2024: ADC Therapeutics Accelerates R&D with Genedata Biologics ADC Therapeutics has partnered with Genedata Biologics, a leading provider of enterprise software for biopharmaceutical R&D ADC Therapeutics utilizes Genedata […]
Weekly Digest – April 2024 Weekly Digest – April 2024 10 Apr 2024: Merck’s $208m acquisition of Abceutics aims to enhance ADC safety Merck & Co. acquired UB’s spinout, Abceutics, for $208 million to enhance ADC safety The deal included […]
Weekly Digest – April 2024 Weekly Digest – April 2024 10 Apr 2024: TORL BioTherapeutics secures $158 million to advance its ADC oncology pipeline through Series B-2 financing TORL BioTherapeutics secures $158 million in Series B-2 financing led by Deep […]
Weekly Digest – April 2024 Weekly Digest – April 2024 9 Apr 2024: BioCity’s first-in-class ADC targeting Glypican 3 clears FDA’s IND application BioCity Biopharma gains FDA clearance for Phase 1 study of BC2027, a first-in-class ADC targeting Glypican 3 […]
